HYPERPHOSPHATEMIA

This study tested a new drug called AP301 in 474 adults with end-stage kidney disease on dialysis who have high phosphorus levels. The goal was to see if AP301 can safely lower phosphorus better than the current standard treatment, sevelamer carbonate. Participants received eithe…

This study tested a drug called MCI-196 to see if it can lower high phosphorus levels in people with advanced kidney disease who are on dialysis. High phosphorus can cause serious health problems. The trial involved 336 adults and compared MCI-196 to a placebo over several weeks.…

This study looked at the long-term safety of a drug called MCI-196 in 116 adults with advanced kidney disease who are on dialysis and have high phosphate levels. The goal was to see if the drug is safe to take over time and if it helps control phosphate levels. Participants took …

This study tested a drug called MCI-196 in 642 adults on dialysis who had high phosphorus and cholesterol levels. The goal was to see if the drug could safely lower these levels, which are linked to heart problems. Participants took either MCI-196 or a placebo for 12 weeks after …

This study tested a drug called MCI-196 in 245 adults on dialysis with high phosphorus levels. After a 12-week dose adjustment period, some patients switched to a placebo to see if MCI-196 kept phosphorus levels lower. The goal was to manage a common complication of kidney failur…

This study tested the long-term safety of a drug called MCI-196 in 632 adults with chronic kidney disease on dialysis who also have high phosphorus levels. Participants took the drug for up to 52 weeks to see how it affected their blood phosphorus and cholesterol. The goal was to…

This study looked at how colestilan, a drug for high phosphate levels in kidney disease, changes the way the body absorbs candesartan, a blood pressure medicine. Eighteen healthy men took candesartan alone or at different times around colestilan doses. The goal was to see if taki…